












Jen Herbach
Founder at Adventris Pharmaceuticals
Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.
Follow Jen
Previously at

Amunix Pharmaceuticals
FLX BIO

Exelixis

Clovis Oncology
InterMune/Genentech
Onyx Pharma/Amgen
Alumnus of

Harvard Business School

University of Cambridge

Amherst College